Overview of China's Market Approval Policy Med Insurance Payment System
Rare disease patients in China face many challenges. Rare diseases can be challenging to diagnose. Even when patients are diagnosed, they cannot get access to efficacious treatment as there are no available drugs in China, or the approved drugs are not intended for rare disease treatments. Moreover, patients cannot afford approved drugs due to their lack of reimbursement coverage. Among them, inaccessibility and unaffordability are the most prominent causes, making more than half of patients unable to receive timely and sufficient treatment.
In this whitepaper, hear from Parexel rare disease consultants on the following topics:
- Relevant Policies on Expedited Approval of Rare Disease Drugs
- An Overview of China’s Multi-Layered Reimbursement System for Rare Disease Drugs
Related Insights
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance
Jun 17, 2025
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Video
Insights with Goldman Sachs Part 6: Generating investor interest
Jan 26, 2024
Video
Insights with Goldman Sachs Part 2: How pharma is using M&A for growth and innovation
Jan 26, 2024
Video
Insights with Goldman Sachs Part 1: Future predictions
Jan 26, 2024
Report
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Blog
Early Scientific Advice in cost effectiveness markets – how to navigate it and is it worth it?
Jun 14, 2023
Related Insights
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance
Jun 17, 2025
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Video
Insights with Goldman Sachs Part 6: Generating investor interest
Jan 26, 2024
Video
Insights with Goldman Sachs Part 2: How pharma is using M&A for growth and innovation
Jan 26, 2024
Video
Insights with Goldman Sachs Part 1: Future predictions
Jan 26, 2024
Report
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Blog
Early Scientific Advice in cost effectiveness markets – how to navigate it and is it worth it?
Jun 14, 2023